Trial Profile
Multiple, fixed-dose, comparative efficacy and safety evaluation of RGB-02 and Neulasta® in patients undergoing chemotherapy treatment known to induce neutropenia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2019
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary) ; Docetaxel; Doxorubicin
- Indications Neutropenia
- Focus Registrational; Therapeutic Use
- Sponsors Gedeon Richter
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
- 20 May 2015 New trial record